Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Combination of Chemotherapy and Mild Hyperthermia Using Targeted Nanoparticles: A Potential Treatment Modality for Breast Cancer

I. Kaur, T. Tieu, VG. Deepagan, MA. Ali, F. Alsunaydih, D. Rudd, MA. Moghaddam, L. Bourgeois, TE. Adams, KJ. Thurecht, M. Yuce, A. Cifuentes-Rius, NH. Voelcker

. 2023 ; 15 (5) : . [pub] 20230430

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23009876

Grant support
GNT1112432 National Health and Medical Research Council

Despite the clinical benefits that chemotherapeutics has had on the treatment of breast cancer, drug resistance remains one of the main obstacles to curative cancer therapy. Nanomedicines allow therapeutics to be more targeted and effective, resulting in enhanced treatment success, reduced side effects, and the possibility of minimising drug resistance by the co-delivery of therapeutic agents. Porous silicon nanoparticles (pSiNPs) have been established as efficient vectors for drug delivery. Their high surface area makes them an ideal carrier for the administration of multiple therapeutics, providing the means to apply multiple attacks to the tumour. Moreover, immobilising targeting ligands on the pSiNP surface helps direct them selectively to cancer cells, thereby reducing harm to normal tissues. Here, we engineered breast cancer-targeted pSiNPs co-loaded with an anticancer drug and gold nanoclusters (AuNCs). AuNCs have the capacity to induce hyperthermia when exposed to a radiofrequency field. Using monolayer and 3D cell cultures, we demonstrate that the cell-killing efficacy of combined hyperthermia and chemotherapy via targeted pSiNPs is 1.5-fold higher than applying monotherapy and 3.5-fold higher compared to using a nontargeted system with combined therapeutics. The results not only demonstrate targeted pSiNPs as a successful nanocarrier for combination therapy but also confirm it as a versatile platform with the potential to be used for personalised medicine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23009876
003      
CZ-PrNML
005      
20230721095419.0
007      
ta
008      
230707s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics15051389 $2 doi
035    __
$a (PubMed)37242631
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kaur, Ishdeep $u Monash Institute of Pharmacy and Pharmaceutical Sciences, Monash University, 381, Royal Parade, Parkville, VIC 3052, Australia $1 https://orcid.org/0000000255509766
245    10
$a Combination of Chemotherapy and Mild Hyperthermia Using Targeted Nanoparticles: A Potential Treatment Modality for Breast Cancer / $c I. Kaur, T. Tieu, VG. Deepagan, MA. Ali, F. Alsunaydih, D. Rudd, MA. Moghaddam, L. Bourgeois, TE. Adams, KJ. Thurecht, M. Yuce, A. Cifuentes-Rius, NH. Voelcker
520    9_
$a Despite the clinical benefits that chemotherapeutics has had on the treatment of breast cancer, drug resistance remains one of the main obstacles to curative cancer therapy. Nanomedicines allow therapeutics to be more targeted and effective, resulting in enhanced treatment success, reduced side effects, and the possibility of minimising drug resistance by the co-delivery of therapeutic agents. Porous silicon nanoparticles (pSiNPs) have been established as efficient vectors for drug delivery. Their high surface area makes them an ideal carrier for the administration of multiple therapeutics, providing the means to apply multiple attacks to the tumour. Moreover, immobilising targeting ligands on the pSiNP surface helps direct them selectively to cancer cells, thereby reducing harm to normal tissues. Here, we engineered breast cancer-targeted pSiNPs co-loaded with an anticancer drug and gold nanoclusters (AuNCs). AuNCs have the capacity to induce hyperthermia when exposed to a radiofrequency field. Using monolayer and 3D cell cultures, we demonstrate that the cell-killing efficacy of combined hyperthermia and chemotherapy via targeted pSiNPs is 1.5-fold higher than applying monotherapy and 3.5-fold higher compared to using a nontargeted system with combined therapeutics. The results not only demonstrate targeted pSiNPs as a successful nanocarrier for combination therapy but also confirm it as a versatile platform with the potential to be used for personalised medicine.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tieu, Terence $u Monash Institute of Pharmacy and Pharmaceutical Sciences, Monash University, 381, Royal Parade, Parkville, VIC 3052, Australia
700    1_
$a Deepagan, Veerasikku G $u Monash Institute of Pharmacy and Pharmaceutical Sciences, Monash University, 381, Royal Parade, Parkville, VIC 3052, Australia
700    1_
$a Ali, Muhammad A $u Department of Electrical and Computer Systems Engineering, Monash University, Clayton Campus, Clayton, VIC 3168, Australia $1 https://orcid.org/0000000199923857
700    1_
$a Alsunaydih, Fahad $u Department of Electrical and Computer Systems Engineering, Monash University, Clayton Campus, Clayton, VIC 3168, Australia
700    1_
$a Rudd, David $u Monash Institute of Pharmacy and Pharmaceutical Sciences, Monash University, 381, Royal Parade, Parkville, VIC 3052, Australia $1 https://orcid.org/000000033104309X
700    1_
$a Moghaddam, Maliheh A $u Centre of Polymer Systems, Tomas Bata University, 5678, 760 01 Zlin, Czech Republic $1 https://orcid.org/0000000162674113
700    1_
$a Bourgeois, Laure $u Monash Centre for Electron Microscopy, Clayton Campus, Monash University, Clayton, VIC 3168, Australia
700    1_
$a Adams, Timothy E $u Commonwealth Scientific and Industrial Research Organization (CSIRO), 343, Royal Parade, Parkville, VIC 3052, Australia
700    1_
$a Thurecht, Kristofer J $u Australian Institute for Bioengineering and Nanotechnology (AIBN), Corner College and Cooper Rds, The University of Queensland, Brisbane, QLD 4072, Australia $1 https://orcid.org/0000000241003131
700    1_
$a Yuce, Mehmet $u Department of Electrical and Computer Systems Engineering, Monash University, Clayton Campus, Clayton, VIC 3168, Australia
700    1_
$a Cifuentes-Rius, Anna $u Monash Institute of Pharmacy and Pharmaceutical Sciences, Monash University, 381, Royal Parade, Parkville, VIC 3052, Australia $1 https://orcid.org/0000000294782239
700    1_
$a Voelcker, Nicolas H $u Monash Institute of Pharmacy and Pharmaceutical Sciences, Monash University, 381, Royal Parade, Parkville, VIC 3052, Australia $u Melbourne Centre for Nanofabrication, Victorian Node of the Australian National Fabrication Facility, Clayton, VIC 3168, Australia $1 https://orcid.org/0000000215367804
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 15, č. 5 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37242631 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095413 $b ABA008
999    __
$a ok $b bmc $g 1958544 $s 1196140
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 5 $e 20230430 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a GNT1112432 $p National Health and Medical Research Council
LZP    __
$a Pubmed-20230707

Find record

Citation metrics

Archiving options